Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines

Journal of Cellular Physiology

Volumn 193, Issue 3, 2002, Pages 340-348

  Shiratsuchi, Toru ^a   Ishibashi, Hiroaki ^a   Shirasuna, Kanemitsu ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; MATRIGEL; METALLOPROTEINASE; OLIGODEOXYNUCLEOTIDE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; TRANSCRIPTION FACTOR AP 1; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; CARCINOMA CELL; CELL INVASION; CELL MOTILITY; EXTRACELLULAR MATRIX; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; DEXAMETHASONE; DNA; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; OLIGODEOXYRIBONUCLEOTIDES; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036888512     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10181     Document Type: Article

References (48)

1. Andreasen PA, Nielsen LS, Kristensen P, Grøndahl-Hansen J, Skriver L, Danø K. 1986. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 17:7644-7651.
2. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. 1997. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 72:1-22.
3. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noel A. 1997. Involvement of PA/Plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405:157-162.
4. Beppu M, Ikebe T, Shirasuna K. 2001. The inhibitory effects of immunosuppressive factors, dexamethasone and interleukin-4, on NF-κB-mediated protease production by oral cancer. Biochim Biophys Acta 1586:11-22.
5. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. 1989. Prolonged activation ofjun and collagenase genes by tumour necrosis factor-alpha. Nature 337:661-663.
6. 5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 59:5307-5314.
7. Chen WT. 1992. Membrane proteases: Roles in tissue remodeling and tumor invasion. Curr Opin Cell Biol 4:802-809.
8. Cohen RL, Xi XP, Crowley CW, Lucas BK, Levinson AD, Shuman MA. 1991. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 78:479-487.
9. Conse M, Blasi F. 1995. Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation. Biol Chem Hoppe Seyler 376:143-155.
10. Dang J, Boyd D, Wang H, Allgayer H, Doe WF, Wang Y. 1999. A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Eur J Biochem 264:92-99.
11. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. 1985. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266.
12. DeClerck YA, Laug WE. 1996. Plasminogen activators and their inhibitors: Cooperation between matrixmetalloproteinases and the plasminogen activator-plasmin system in tumor progression. Enzyme Protein 49:72-84.
13. Greenberg ME, Ziff EB. 1984. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature 311:433-438.
14. Hayashido Y, Shirasuna K, Sugiura T, Nakashima M, Matsuya T. 1996. Effect of dexamethasone on invasion of human squamous cell carcinoma cells into collagen gel. Cancer Lett 108:81-86.
15. Hewitt RE, Powe DG, Carter GI, Turner DR, Price JE. 1992. Basement membrane collagen-IV synthesis in colorectal tumours. Int J Cancer 51:530-536.
16. Ikebe T, Takeuchi H, Jimi E, Beppu M, Shinohara M, Shirasuna K. 1998. Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma. Int J Cancer 77:578-585.
17. Imbra RJ, Karin M. 1987. Metallothionein gene expression is regulated by serum factors and activators of protein kinase C. Mol Cell Biol 7:1358-1363.
18. Ishibashi H, Nakagawa K, Onimaru M, Castellanous EJ, Kaneda Y, Nakashima Y, Shirasuna K, Sueishi K. 2000. Spl decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor Β1, and tissue factor and also cell growth and invasion activities. Cancer Res 60:6531-6536.
19. Izumi H, Ono M, Ushiro S, Kohno K, Kung HF, Kuwano M. 1994. Cross talk of tumor necrosis factor-α and epidermal growth factor in human microvascular endothelial cells. Exp Cell Res 214:654-662.
20. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P. 1990. Antitumor promotion and anti inflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62:1189-1204.
21. Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, Takeuchi H, Shirasuna K. 1999. Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: Correlations with tumor invasion and metastasis. Head Neck 21:627-638.
22. Laiho M, Keski-Oja J. 1989. Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res 49:2533-2553.
23. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. 1981. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41:4629-4636.
24. Malliri A, Symons M, Hurlstone AF, Lamb RF, Wheeler T, Ozanne BW. 1998. The transcription factor AP-1 is required for EGF-induced activation of Rho-like GTPases, cytoskeletal rearrangements, motility, and in vitro invasion ofA431 cells. J Cell Biol 143:1087-1099.
25. Mannucci PM. 1998. Hemostatic drugs. New Engl J Med 339:245-253.
26. Murakami N, Fukuchi S, Takeuchi K, Hori T, Shibamoto S, Ito F. 1998. Antagonistic regulation of cell migration by epidermal growth factor and glucocorticoid in human gastric carcinoma cells. J Cell Physiol 176:127-137.
27. Nerlov C, De Cesare D, Pergola F, Caracciolo A, Blasi F, Johnsen M, Verde P. 1992. A regulatory element that mediates co-operation between a PEA3-AP-1 element and AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 12:4573-4582.
28. Niedbala MJ, Sartorelli AC. 1989. Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix. Cancer Res 49:3302-3309.
29. Okimoto T, Kohno K, Kuwano M, Gopas J, Kung HF, Ono M. 1996. Regulation of epidermal growth factor receptor by activated H-ras and V-myc oncogenes in mouse Balb/3T3 cells: Possible roles of AP-1. Oncogene 12:1625-1633.
30. Ossowski L. 1992. Invasion of connective tissue by human carcinoma cell lines: Requirement for urokinase, urokinase receptor, and interstitial collagenases. Cancer Res 52:6754-6760.
31. Ossowski L, Aguirre Ghiso JA. 2000. Urokinase receptor and integrin partnership: Coordination of signaling for cell adhesion, migration, and growth. Curr Opin Cell Biol 12:613-620.
32. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. 1991. Cellular receptor for urokinase plasminogen activator: Carboxyterminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 266:1926-1933.
33. Preissner KT, Kanse SM, May AE. 2000. Urokinase receptor: A molecular organizer in cellular communication. Curr Opin Cell Biol 12:621-628.
34. Ray A, Prefontaine KE. 1994. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 91:752-756.
35. Rosenthal EL, Johnson TM, Allen ED, Apel IJ, Punturieri A, Weiss SJ. 1998. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res 58:5221-5230.
36. Sato H, Seiki M. 1993. Regulatory mechanism of Mr 92000 type IV collagenase gene expression, which is associated with invasiveness of tumor cells. Oncogene 8:395-405.
37. Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, Seiki M. 1992. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 7:77-83.
38. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. 1994. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370(6484):61-65.
39. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. 1995. Role of transcriptional activasion of IκBα in mediation of immunosuppression by glucocorticoids. Science 270:283-286.
40. Shirasuna K, Saka M, Hayashido Y, Yoshioka H, Sugiura T, Matsuya T. 1993. Extracellular-matrix production and degradation by adenoid-cystic-carcinoma cells; participation of plasminogen activator and its receptor in matrix degradation. Cancer Res 53:147-152.
41. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. 1993. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541-573.
42. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. 1985. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82:4939-4943.
43. Sugiura T, Shirasuna K, Hayashido Y, Sakai T, Matsuya T. 1996. Effects of human fibroblasts on invasiveness of oral cancer cells in vitro: Isolation ofa chemotactic factor from human fibroblasts. Int J Cancer 68:774-781.
44. Towle MJ, Lee A, Maduakor MC, Schwartz E, Bridges AJ, Littlefield BA. 1993. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: An important new class of selective synthetic urokinase inhibitor. Cancer Res 53:2553-2559.
45. Tryggvason K, Hoyhtya M, Salo T. 1987. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907:191-217.
46. Vassalli JD, Belin D. 1987. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 214:187-191.
47. Waltz DA, Chapman HA. 1994. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269:14746-14750.
48. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, Karin M. 1990. Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62:1205-1215.